Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | TLR4 | O00206 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16520421 | 0.81 | ALDH1A1 (0.34) | MEN1KMT2AMAPT | |
| SCHEMBL15176174 | 0.78 | MAOB (0.41) | MAOBMEN1KMT2AFFAR1 | |
| SCHEMBL15173719 | 0.70 | MAOA (0.57) | MAOBMAOATLR4TLR2MAPT | |
| SCHEMBL16508018 | 0.70 | MAOA (0.57) | MAOBMAOATLR4TLR2MAPT | |
| SCHEMBL6035928 | 0.69 | MAOB (0.49) | MAOBMAOAALOX5FFAR1 | |
| SCHEMBL6035769 | 0.69 | MAOB (0.51) | MAOBMAOAALOX5MEN1KMT2A | |
| SCHEMBL22181455 | 0.68 | ABCB1 (0.44) | MAOBMAOAMEN1KMT2AMAPT | |
| SCHEMBL17386359 | 0.68 | MAOB (0.50) | MAOBMAOAALOX5MAPT | |
| SCHEMBL16097608 | 0.68 | MAOB (0.50) | MAOBMAOAALOX5MEN1KMT2A | |
| SCHEMBL22181587 | 0.68 | KDM1A (0.49) | MAOBMAOAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417419-A1 | C-TERMINAL HSP90 INHIBITORS | UNIV KANSAS (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4403552-A2 | C-TERMINAL HSP90-INHIBITORS | The University of Kansas (US) | 2024-07-24 | — | — | EP | disclosed |
| US-12024536-B2 | C-terminal HSP90 inhibitors | UNIVERSITY OF KANSAS (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230102047-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11390640-B2 | C-terminal Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2022-07-19 | — | — | US | disclosed |
| US-20210188891-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10882881-B2 | C-terminal Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200283465-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2020-09-10 | — | — | US | disclosed |
| EP-3656758-A1 | INTERMEDIATES FOR THE PREPARATION OF C-TERMINAL HSP90 INHIBITORS | The University of Kansas (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10590157-B2 | C-terminal HSP90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-03-17 | — | — | US | disclosed |
| EP-2812341-B1 | C-TERMINAL HSP90 INHIBITORS | UNIV KANSAS (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190023730-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2019-01-24 | — | — | US | disclosed |
| US-10030041-B2 | C-terminal Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170051000-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9422320-B2 | C-terminal HSP90 inhibitors | UNIVERSITY OF KANSAS (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150057240-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882881-B2 | C-terminal Hsp90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-11390640-B2 | C-terminal Hsp90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-20230102047-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-10590157-B2 | C-terminal HSP90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-20240417419-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-10030041-B2 | C-terminal Hsp90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-20150057240-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-12024536-B2 | C-terminal HSP90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-20210188891-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-20170051000-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-20190023730-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
| US-20200283465-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | MAOB 4134/4885MAOA 4412/4885TLR4 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.